Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. “We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to ...

Core Insights - Recursion Pharmaceuticals has seen a 27% decline in share price year-to-date and is trading over 55% below its 52-week high of $12, yet it continues to attract interest due to its innovative AI-driven drug discovery approach [2] - The company's primary asset, Recursion OS, utilizes automation and machine learning to enhance drug discovery, potentially accelerating the development process significantly [3] - Recursion OS has commercial potential beyond the company's own projects, as it can be licensed to other pharmaceutical firms, with existing partnerships with Roche and Genentech [4] Financial Performance - Over the past four quarters, Recursion reported a net loss of $575 million, resulting in a net margin of -961%, and an operating cash flow of -$389 million, corresponding to a margin of -650% [5] - Despite operational losses, the company maintains a strong financial position with low debt of $93 million against a market capitalization of $2.1 billion, leading to a debt-to-equity ratio of 4.4% [6] - Recursion has $500 million in cash and cash equivalents, representing 38.3% of its total assets of $1.3 billion, providing a solid runway for ongoing operations [6] Growth Potential - Recursion's revenue primarily comes from collaboration agreements with pharmaceutical partners, which validate its AI-driven platform and provide immediate financial support [7] - The merger with Exscientia has resulted in a combined pipeline with projected peak sales potential exceeding $1 billion, highlighting the long-term revenue potential for investors [8][9] - The licensing of Recursion OS could serve as an additional revenue source, enhancing the company's financial outlook [9]

Transaction Overview - Recursion and Exscientia are combining to bring better medicines to patients more rapidly and cost efficiently[11] - Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share[27] - Recursion shareholders will own approximately 74% of the combined company, while Exscientia shareholders will own approximately 26%[27] - The transaction is expected to close by early 2025, subject to shareholder approvals and closing conditions[27] Financial Synergies and Cash Position - The combined company will have approximately $850 million in cash as of the end of Q2 2024[11, 27] - Estimated annual synergies of $100 million or more are expected[11, 27] - The pro forma combined financial plans are expected to extend the cash runway into 2027[27] Pipeline and Partnerships - The combined company anticipates approximately 10 clinical readouts over the next 18 months[11, 12, 14] - Current partnerships have the potential for over $200 million in milestone payments over the next 2 years[11, 18] - The combined company has the potential for over $20 billion in total revenue before royalties from partners[18] - CDK4/6 inhibitors generated $11 billion in sales in 2023[31]

Financial Status - Enanta Pharmaceuticals reported a strong balance sheet with $193.4 million in cash as of March 31, 2025[6] - The company is leveraging ongoing royalties to support its robust pipeline[6] Respiratory Syncytial Virus (RSV) - Zelicapavir (EDP-938) - Zelicapavir is the only N-inhibitor in clinical development for RSV[17] - A Phase 2 pediatric study showed a viral load decline of 1.18 log at Day 5 in a prespecified subset of patients[25] - A Phase 2 pediatric study showed a viral load decline of 1.4 log at the end of treatment in Part 2[30] - EDP-323, an RSV L-protein inhibitor, demonstrated an 85-87% reduction in viral load AUC in a human challenge model[42] Immunology - KIT Inhibitor (EPS-1421) - EPS-1421 inhibits KIT with nanomolar potency in both binding and cellular assays[63] - EPS-1421 exhibits greater than 500-fold selectivity for KIT over other KIT family members[68] - In mice, EPS-1421 inhibits SCF-mediated histamine release with an EC50 (free drug) of 0.25nM[65] Immunology - STAT6 Inhibitor - Prototype STAT6 inhibitors exhibit nanomolar inhibition in biochemical and cellular assays[84] - Prototype STAT6 inhibitor demonstrates good selectivity, with greater than 1000x biochemical selectivity for STAT6 over other STATs[88] - Prototype STAT6 oral inhibitor results in complete inhibition of pSTAT6 in a mouse model[93]

Corporate Strategy & Financial Position - BioNTech plans to strengthen its position through the acquisition of Biotheus, securing global control of BNT327 and expanding its immunotherapy capabilities[8] - The company reported a strong balance sheet with approximately €174 billion in total cash, cash equivalents, and security investments as of December 31, 2024[8] Oncology Pipeline & Clinical Development - BioNTech is advancing its oncology portfolio with 15 ongoing Phase 2 and Phase 3 trials[8] - BNT327 is being studied in 20+ clinical trials across multiple indications, with 3 global potentially registrational trials planned[36] - BNT327, in combination with chemotherapy, demonstrated a 738% objective response rate (ORR) in the ITT population in 1L TNBC[40] - Autogene cevumeran induced neoantigen-specific T cell responses in 71% of patients in a first-in-human study[65] mRNA Cancer Immunotherapy & Technology - BioNTech is prioritizing novel mRNA cancer immunotherapy, including FixVac and iNeST, targeting tumor-associated antigens and mutations[24] - The company has treated >450 patients and selected 18000 neoantigens using its iNeST platform[15] - BioNTech is leveraging AI to enhance its scientific capabilities and pioneer personalized immunotherapies[12] 2025 Priorities & Outlook - In 2025, BioNTech expects multiple randomized Phase 2 data readouts and will execute 7 ongoing Phase 2 trials and first novel combination trials[91] - The company aims to advance 3 global registration-enabling trials in potential fast-to-market indications in 2025[92]

Industry Overview - The biotech industry has shown resilience amid global trade tensions, with ongoing geopolitical issues presenting challenges, yet the demand for innovative medical treatments remains strong [1] - Strategic collaborations and acquisitions are increasingly common as large pharma and biotech companies seek to expand their product portfolios and pipelines, particularly in the context of AI-driven drug discovery [2][9] - The Zacks Biomedical and Genetics industry is currently ranked 86, placing it in the top 35% of over 246 Zacks industries, indicating a decent outlook driven by consistent demand for medical advancements [15] Market Trends - The focus on high-profile drug performance and innovative pipeline development is critical, with significant R&D expenditures required to create breakthrough treatments [6] - Successful commercialization is essential for drug uptake, often leading smaller biotech firms to collaborate with larger companies for shared sales or royalties [7] - The recent emphasis on AI technology for drug discovery is expected to attract further investment into the biotech sector [11] Company Performance - Exelixis, Inc. (EXEL) is positioned well with its lead drug, Cabometyx, which is gaining traction in the oncology market, and its shares have surged 31% year to date [35][36] - Verona Pharma (VRNA) has seen a 94.8% increase in shares year to date, driven by the uptake of its drug Ohtuvayre for COPD, with further growth anticipated [24] - Alkermes (ALKS) is benefiting from strong sales of its proprietary drugs and has a Zacks Rank of 1, with EPS estimates for 2025 rising to $1.79 [26][27] - Immunocore Holdings (IMCR) focuses on TCR bispecific immunotherapies and has gained 11.4% year to date, with ongoing studies expected to enhance its market position [30][32] - Kiniska Pharmaceuticals (KNSA) is experiencing growth with its FDA-approved drug Arcalyst and has seen a 37.7% increase in shares [39][40]

Core Insights - XtalPi is expanding its research collaboration with Pfizer to develop a next-generation molecular modeling platform aimed at enhancing drug discovery processes through improved accuracy and speed of AI models [1][3][4] Company Overview - XtalPi Holdings Limited, founded in 2015 by MIT physicists, integrates quantum physics, AI, and robotics to provide innovative R&D solutions across various industries including pharmaceuticals and materials science [5] Collaboration Details - The collaboration will focus on creating more accurate predictive models tailored to Pfizer's proprietary chemical space, enhancing small molecule drug discovery and development [3] - XtalPi will utilize its XFEP platform for parameter customization and Free Energy Perturbation calculations to support Pfizer's drug discovery efforts [3] Technological Advancements - The first-generation XtalPi Force Field (XFF) demonstrated superior performance in predicting small molecule geometry and binding affinity, crucial for drug screening and rational design [2] - The new platform aims to deliver accurate predictive tools with significantly improved throughput, enhancing the efficiency of drug development [1][3]

How much do you think AI is going to be a gamecher not just in your work but maybe even in helping compensate for some of the declines in funding. Oh, I think AI is a gamecher already and I'm very bullish about what that means in healthcare and in science. So on the scientific discovery side certainly AI is already helping us instead of you know make make very large calculated assessments by of data analysis instead of testing one hypothesis at a time we can test millions in a minute.So without question for ...

Investor Presentation May 2025 1 January 14, 2025 Safe Harbor / Non-GAAP financial measures This presentation contains forward-looking statements within the meaning of the federal securities laws. Statements in this presentation which are not strictly historical statements including, without limitation, express or implied statements or guidance regarding Repligen's financial results for full year 2025, future financial performance and other statements identified by words like "estimated," "anticipated," "gu ...

Core Insights - iBio, Inc. is set to announce a third target in its collaboration with AstralBio, focusing on advancements in obesity and cardiometabolic disease treatments [1][2] - The company aims to pioneer next-generation antibody medicines that are targeted, longer-lasting, and potentially better tolerated, with a strategic overview of its obesity treatment strategy [2][4] Company Overview - iBio is a biotech company utilizing AI and advanced computational biology to develop biopharmaceuticals for various diseases, including cardiometabolic diseases, obesity, and cancer [4] - The company combines proprietary 3D modeling with innovative drug discovery platforms to create a pipeline of breakthrough antibody treatments addressing significant unmet medical needs [4] Upcoming Events - A conference call is scheduled for June 24, 2025, at 8:30 a.m. ET to discuss the latest advancements and the new target in the AstralBio collaboration [1][3]